ArticleNPJ precision oncology2021
TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study.
Open access · goldAbstract read
In one paragraph
Article in NPJ precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 23% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Circulating IL-17 reduces the risk of cisplatin-induced hearing loss in children: a bidirectional two-sample Mendelian randomization study.Scientific reports · 2023Pooled it
- Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review.BMC cancer · 2022Pooled it
- Prestin as a potential biomarker for cochlear injury: Current evidence and future directions.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Review
- Navigating the Genetic Risk of Chemotherapy-Induced Hearing Loss in the Stria Vascularis.Clinical pharmacology and therapeutics · 2026Review
- Inherited immune traits and cisplatin-induced ototoxicity in cancer patients: a Mendelian randomization study.International journal of clinical pharmacy · 2026Article
- Article
- Article
- Article
- Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin Chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Approaches to Reduce Toxicity in Pediatric Brain Tumors.Current oncology (Toronto, Ont.) · 2025Review
- Comparison of associations suggests mainly distinct pools of genetic risk factors contribute to cisplatin-induced hearing loss and hearing difficulty in the general population.Frontiers in pharmacology · 2025Article
- Leveraging large-scale datasets and single cell omics data to develop a polygenic score for cisplatin-induced ototoxicity.Human genomics · 2024Article
- Cognitive Skills and DNA Methylation Are Correlating in Healthy and Novice College Students Practicing Preksha Dhyāna Meditation.Brain sciences · 2023Article
- Clinical and genome-wide association analysis of chemoradiation-induced hearing loss in nasopharyngeal carcinoma.Human genetics · 2023Article
- Special considerations in the design and implementation of pediatric otoprotection trials.Journal of cancer survivorship : research and practice · 2023Review
- Chemotherapy Side-Effects: Not All DNA Damage Is Equal.Cancers · 2022Review
- Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia.Frontiers in pharmacology · 2022Article
- TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study.NPJ precision oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
57 authors at 20 institutions in 9 countries.
A J M Meijer *Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. a.j.m.meijer-16@prinsesmaximacentrum.nl.ORCID http://orcid.org/0000-0003-1631-0006
F A Diepstraten *Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-2507-1820
T Langer *Department of Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck, Germany.
L BroerDepartment of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
I K DomingoDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada.
E ClemensPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
A G UitterlindenDepartment of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0002-7276-3387
A C H de VriesPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
M van GrotelPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
W P VermeijPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-9690-1385
R A OzingaPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
H BinderGerman Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
J ByrneBoyne Research Institute, Drogheda, Ireland.
E van Dulmen-den BroederPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
M L GarrèDepartment of Neurooncology, IRCCS Istituto Giannina Gaslini, Genova, Italy.
D GrabowGerman Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
P KaatschGerman Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
M KaiserGerman Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
L KenborgChildhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark.
J F WintherChildhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark.
C RechnitzerDepartment of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
H HasleDepartment of Pediatrics, Aarhus University Hospital, Aarhus, Denmark.ORCID http://orcid.org/0000-0003-3976-9231
T KepakUniversity Hospital Brno, Brno, Czech Republic.ORCID http://orcid.org/0000-0002-1449-5273
K KepakovaUniversity Hospital Brno, Brno, Czech Republic.
W J E TissingPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
A L F van der KooiPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-0497-3814
L C M KremerPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
J KruseovaDepartment of Children Hemato-Oncology, Motol University Hospital Prague, Prague, Czech Republic.
S M F PluijmPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
C E KuehniInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0001-8957-2002
H J H van der PalPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
R ParfittDepartment of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany.
C SpixGerman Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
A TillmannsDepartment of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany.
D DeusterDepartment of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany.
P MatulatDepartment of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany.
G CalaminusPediatric Hematology and Oncology, University Children's Hospital Muenster, Muenster, Germany.
A E HoetinkDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospital Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-7417-5546
S ElsnerInstitute of Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany.
J GebauerDepartment of Internal Medicine, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
R HauptEpidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, Genova, Italy.
H LacknerDepartment of Pediatric and Adolescent Medicine, Medical University of Graz, Graz, Austria.
C BlattmannDepartment of Pediatric Oncology/Hematology/Immunology, Stuttgart Cancer Center, Olgahospital, Stuttgart, Germany.
S J C M M NeggersPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
S R RassekhBC Children's Hospital Research Institute, Vancouver, BC, Canada.
G E B WrightBC Children's Hospital Research Institute, Vancouver, BC, Canada.
B BrooksAudiology and Speech Pathology Department, BC Children's Hospital, Vancouver, BC, Canada.
A P NagtegaalDepartement of Otorhinolaryngology, Erasmus Medical Center, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0001-8128-7178
B I DrögemöllerBC Children's Hospital Research Institute, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-3348-5855
C J D RossBC Children's Hospital Research Institute, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0003-1476-7037
A P BhavsarDepartment of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada.
A G Am Zehnhoff-DinnesenDepartment of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany.
B C CarletonBC Children's Hospital Research Institute, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-4485-4054
O ZolkInstitute of Clinical Pharmacology, Brandenburg Medical School, Rüdersdorf, Germany.ORCID http://orcid.org/0000-0002-8220-3834
M M van den Heuvel-EibrinkPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-7760-879X
PanCareLIFE Consortium
and the CPNDS Consortium
Princess Máxima Center · NLUniversity Hospital Münster · DEUniversity of British Columbia · CAAmsterdam UMC Location University of Amsterdam · NLErasmus MC · NLJohannes Gutenberg University Mainz · DEAarhus University Hospital · DKIstituto Giannina Gaslini · ITOncode Institute · NLUniversity Hospital Brno · CZUniversity of Alberta · CAUniversity of Bern · CHBC Children's Hospital · CABoyne Research Institute · IECopenhagen University Hospital · DKDanish Cancer Society · DKMedical University of Graz · ATOlgahospital · DEUniversity Hospital in Motol · CZUniversity Hospital Schleswig-Holstein · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) approach, we identified a genetic variant in TCERG1L (rs893507) to be associated with hearing loss in 390 non-cranial irradiated, cisplatin-treated children with cancer. These results were replicated in two independent, similarly treated cohorts (n = 192 and 188, respectively) (combined cohort: P = 5.3 × 10
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.